175 related articles for article (PubMed ID: 30376134)
1. AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
Lu J; Hu S; Wang W; Li J; Dong Z; Zhou J; Hai X
Toxicol Sci; 2018 Nov; 166(1):219-227. PubMed ID: 30376134
[TBL] [Abstract][Full Text] [Related]
2. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
[TBL] [Abstract][Full Text] [Related]
4. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As
Guo M; Li J; Fan S; Liu W; Wang B; Gao C; Zhou J; Hai X
J Pharm Biomed Anal; 2019 Jul; 171():212-217. PubMed ID: 31009876
[TBL] [Abstract][Full Text] [Related]
5. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
[No Abstract] [Full Text] [Related]
6. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
[TBL] [Abstract][Full Text] [Related]
7. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the AS3MT gene are associated with arsenic methylation capacity and damage to the P21 gene in arsenic trioxide plant workers.
Ni G; Tan J; Wang M; Ping N; Liu M; He Y
Toxicol Ind Health; 2021 Dec; 37(12):727-736. PubMed ID: 34730462
[TBL] [Abstract][Full Text] [Related]
11. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
[TBL] [Abstract][Full Text] [Related]
12. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Zhu HH; Hu J; Lo-Coco F; Jin J
Blood; 2019 Aug; 134(7):597-605. PubMed ID: 31113776
[TBL] [Abstract][Full Text] [Related]
13. No Association of AS3MT Gene Polymorphisms with Susceptibility to Hepatotoxicity in APL Patients Treated with AS2O3: A Single-Center Study.
Joneidi Z; Mortazavi Y; Chahardouli B; Rostami S; Vaezi M; Nabipour M; Biglari A; Ghavamzadeh A
Int J Hematol Oncol Stem Cell Res; 2023 Oct; 17(4):281-290. PubMed ID: 38076777
[No Abstract] [Full Text] [Related]
14. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
17. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X
Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065
[TBL] [Abstract][Full Text] [Related]
18. AS3MT, GSTO, and PNP polymorphisms: impact on arsenic methylation and implications for disease susceptibility.
Antonelli R; Shao K; Thomas DJ; Sams R; Cowden J
Environ Res; 2014 Jul; 132():156-67. PubMed ID: 24792412
[TBL] [Abstract][Full Text] [Related]
19. Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
Maimaitiyiming Y; Wang C; Xu S; Islam K; Chen YJ; Yang C; Wang QQ; Naranmandura H
Metallomics; 2018 Jun; 10(6):828-837. PubMed ID: 29774349
[TBL] [Abstract][Full Text] [Related]
20. Association between arsenic (+3 oxidation state) methyltransferase gene polymorphisms and arsenic methylation capacity in rural residents of northern China: a cross-sectional study.
Zhang M; Xu H; Lou Q; Zhang Z; Zhang X; Yin F; Lv M; Zhang Y; Yin Y; Gao Y; Liu X; Yang Y
Arch Toxicol; 2023 Nov; 97(11):2919-2928. PubMed ID: 37658865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
